Tags

Type your tag names separated by a space and hit enter

Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations.
Ther Adv Hematol 2019; 10:2040620719861475TA

Abstract

Coronary artery disease and peripheral arterial disease are strong predictors of risk for a future ischemic event. Despite the utilization of effective secondary prevention strategies, the prevalence of ischemic recurrences remains high, underscoring the need for effective secondary prevention antithrombotic treatment regimens. To date, most of the tested approaches have been with the use of antiplatelet therapies, used either individually or in combination. However, most recent findings support the potential role of oral anticoagulant therapy in addition to antiplatelet therapy to reduce the risk of ischemic recurrences. This approach has been tested in both acute and stable settings of patients with cardiovascular disease manifestations. The present manuscript provides an overview on the rationale and clinical trial updates on the role of oral anticoagulant therapy, in particular rivaroxaban used at the so-called vascular protection dose, in adjunct to antiplatelet therapy (i.e. aspirin), a strategy known as dual pathway inhibition, for secondary prevention of ischemic recurrences in patients with stable atherosclerotic disease manifestations.

Authors+Show Affiliations

Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA.Division of Cardiology, Department of Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA.University of Florida College of Medicine-Jacksonville, 655 West 8th Street, Jacksonville, FL, 32209, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31321012

Citation

Cho, Sung Won, et al. "Role of Oral Anticoagulant Therapy for Secondary Prevention in Patients With Stable Atherothrombotic Disease Manifestations." Therapeutic Advances in Hematology, vol. 10, 2019, p. 2040620719861475.
Cho SW, Franchi F, Angiolillo DJ. Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. Ther Adv Hematol. 2019;10:2040620719861475.
Cho, S. W., Franchi, F., & Angiolillo, D. J. (2019). Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. Therapeutic Advances in Hematology, 10, p. 2040620719861475. doi:10.1177/2040620719861475.
Cho SW, Franchi F, Angiolillo DJ. Role of Oral Anticoagulant Therapy for Secondary Prevention in Patients With Stable Atherothrombotic Disease Manifestations. Ther Adv Hematol. 2019;10:2040620719861475. PubMed PMID: 31321012.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. AU - Cho,Sung Won, AU - Franchi,Francesco, AU - Angiolillo,Dominick J, Y1 - 2019/07/12/ PY - 2019/04/11/received PY - 2019/06/11/accepted PY - 2019/7/20/entrez PY - 2019/7/20/pubmed PY - 2019/7/20/medline KW - coronary artery disease KW - factor Xa inhibitor KW - oral anticoagulant KW - peripheral arterial disease SP - 2040620719861475 EP - 2040620719861475 JF - Therapeutic advances in hematology JO - Ther Adv Hematol VL - 10 N2 - Coronary artery disease and peripheral arterial disease are strong predictors of risk for a future ischemic event. Despite the utilization of effective secondary prevention strategies, the prevalence of ischemic recurrences remains high, underscoring the need for effective secondary prevention antithrombotic treatment regimens. To date, most of the tested approaches have been with the use of antiplatelet therapies, used either individually or in combination. However, most recent findings support the potential role of oral anticoagulant therapy in addition to antiplatelet therapy to reduce the risk of ischemic recurrences. This approach has been tested in both acute and stable settings of patients with cardiovascular disease manifestations. The present manuscript provides an overview on the rationale and clinical trial updates on the role of oral anticoagulant therapy, in particular rivaroxaban used at the so-called vascular protection dose, in adjunct to antiplatelet therapy (i.e. aspirin), a strategy known as dual pathway inhibition, for secondary prevention of ischemic recurrences in patients with stable atherosclerotic disease manifestations. SN - 2040-6207 UR - https://www.unboundmedicine.com/medline/citation/31321012/Role_of_oral_anticoagulant_therapy_for_secondary_prevention_in_patients_with_stable_atherothrombotic_disease_manifestations L2 - http://journals.sagepub.com/doi/full/10.1177/2040620719861475?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -